FLIR Systems Announces Artificial Intelligence Traffic Cameras for Predictive Traffic Management
9.11.2020 16:00:00 EET | Business Wire | Press release
FLIR Systems, Inc. today announced two intelligent traffic system cameras, the FLIR ThermiCam™ AI* with thermal imaging and the FLIR TrafiCam™ AI visible camera, both with artificial intelligence (AI) to optimize traffic flow on roadways and at intersections. When combined with the FLIR Acyclica™ cloud platform, cities can apply the AI-camera data to predict traffic, prevent congestion and potential accidents, and create safer roads for drivers, cyclists, and pedestrians 24 hours a day.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201109005113/en/
Traffic engineers apply data from AI-enabled cameras, FLIR ThermiCam AI and TrafiCam AI, to predict traffic and prevent congestion and potential accidents for safer roads. (Photo: Business Wire)
“FLIR traffic systems are currently installed in 75 countries, and with the addition of ThermiCam AI and TrafiCam AI, FLIR now offers a fully integrated solution that enables traffic engineers and city planners to apply AI-based learnings to continuously optimize traffic flow,” said Rickard Lindvall, General Manager, Solutions Business, FLIR Systems. “The integrated solution enables cities to improve urban roadway design to make cities safer and more livable.”
The AI-enabled cameras help control traffic dynamically at the edge through real-time data capture and processing, and provide input to traffic signal controllers at intersections, which improves traffic flow and safety in the moment. With the ability to capture heat energy data through a thermal sensor within the ThermiCam AI, and a visible low-light, high-definition sensor within the TrafiCam AI, cities’ traffic signals have complete continuous monitoring, in all weather conditions and even through smoke for tunnel monitoring. The cameras are also Wi-Fi enabled for travel time calculations and other origin-destination applications. In the future, the cameras can be retrofitted with 5G cellular antennas to support vehicle-to-everything (V2X) connectivity, which will further improve road safety.
The FLIR Acyclica cloud platform provides the tools and analytics needed to better understand traffic data. When ThermiCam AI and TrafiCam AI are paired with the Acyclica cloud platform, cities can apply their AI-based learnings to real time data to make predictive traffic pattern changes for more efficient and safer cities.
The new AI traffic cameras are available globally in the first quarter of 2021. To learn more about FLIR ThermiCam AI and TrafiCam AI, visit www.flir.com/thermicam-ai and www.flir.com/traficam-ai. For more information about FLIR traffic solutions, visit www.flir.com/traffic/.
*The ThermiCam AI camera is sold as the TrafiSense ™ AI camera in the United States and Canada. To learn more visit www.flir.com/trafisense-ai.
About FLIR Systems, Inc .
Founded in 1978, FLIR Systems is a world-leading industrial technology company focused on intelligent sensing solutions for defense and industrial applications. FLIR Systems’ vision is to be “The World’s Sixth Sense, creating technologies to help professionals make more informed decisions that save lives and livelihoods. For more information, please visit www.flir.com and follow @flir.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201109005113/en/
Contact information
Media Relations:
Eleana Stayer
Phone: +44 7545 204375
Email: eleana.stayer@flir.com
Investor Relations:
Lasse Glassen
Addo Investor Relations
Phone: 424-238-6249
Email: lglassen@addoir.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom